A 3-year study on Progression Free Survival (PFS).  The study’s aim is to contribute an empirically derived patient perspective about the use of progression-free survival as an appropriate endpoint in clinical trials of cancer therapy. PFS is the length of time after cancer treatment that a patient lives with the disease without tests showing that it is worsening. Although PFS is used in clinical trials as a means of testing how well a new treatment might work, a longer PFS does not necessarily mean that overall survival is improved. So if patients derive PFS benefits but overall live no longer and they suffer unacceptable side-effects from the treatment then this PFS may be of little value. This is an extremely important study that has generated much interest already.

Poster presentations

The British Psychosocial Oncology Society (BPOS) Annual Conference 16-17 March 2017 PDF document of trial summary poster

ASCO Cancer Survivorship Symposium, 28th January 2017. PDF document of trial summary poster

ASCO Palliative Care Conference, 23-25 October 2014 PDF document of trial summary poster

 

^ Top